Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin

Postthrombotic syndrome (PTS) is a long‐term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). Pathogenesis is not fully understood but inadequate anticoagulant therapy with vitamin K antagonists is a known risk factor for the development of PTS.

[1]  S. Kahn,et al.  Post‐thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long‐term cross‐sectional follow‐up of RE‐COVER study patients , 2021, Journal of thrombosis and haemostasis : JTH.

[2]  W. Boersma,et al.  Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin , 2021, Research and practice in thrombosis and haemostasis.

[3]  W. Ageno,et al.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. , 2020, Blood advances.

[4]  P. Prandoni,et al.  Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis. , 2020, Thrombosis research.

[5]  W. Ageno,et al.  The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants , 2019, Internal and Emergency Medicine.

[6]  M. Nogueira,et al.  Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. , 2019, Surgery.

[7]  E. V. de Paula,et al.  Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban. , 2019, Vascular pharmacology.

[8]  F. Skjøth,et al.  Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. , 2018, The American journal of medicine.

[9]  S. Kahn,et al.  How I treat the postthrombotic syndrome. , 2018, Blood.

[10]  L. Jelsness-Jørgensen,et al.  Rivaroxaban Versus Warfarin for the Prevention of Post-Thrombotic Syndrome , 2018 .

[11]  E. Vicaut,et al.  Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study , 2018, Thrombosis Journal.

[12]  C. Coleman,et al.  Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism , 2018, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[13]  L. Jelsness-Jørgensen,et al.  Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. , 2018, Thrombosis research.

[14]  S. Kahn,et al.  Epidemiology of the post-thrombotic syndrome. , 2017, Thrombosis research.

[15]  S. Goldhaber,et al.  Pharmacomechanical Catheter‐Directed Thrombolysis for Deep‐Vein Thrombosis , 2017, The New England journal of medicine.

[16]  M. Prins,et al.  Compression therapy for prevention of post-thrombotic syndrome. , 2017, The Cochrane database of systematic reviews.

[17]  P. Poredos,et al.  Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. , 2017, Thrombosis research.

[18]  M. Prins,et al.  Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis , 2016, Thrombosis and Haemostasis.

[19]  C. DiGiovanni,et al.  What is the effect of venous thromboembolism and related complications on patient reported health-related quality of life? , 2016, Thrombosis and Haemostasis.

[20]  T. Wakefield,et al.  The post thrombotic syndrome: Ignore it and it will come back to bite you. , 2016, Blood reviews.

[21]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[22]  S. Kahn,et al.  Guidance for the prevention and treatment of the post-thrombotic syndrome , 2016, Journal of Thrombosis and Thrombolysis.

[23]  H. Tie,et al.  Compression Therapy in the Prevention of Postthrombotic Syndrome , 2015, Medicine.

[24]  M. Prins,et al.  The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation , 2015, Seminars in Thrombosis & Hemostasis.

[25]  P. Prandoni,et al.  The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. , 2014, Circulation.

[26]  D. Aujesky,et al.  The VEINES-QOL/Sym questionnaire is a reliable and valid disease-specific quality of life measure for deep vein thrombosis in elderly patients , 2014, Quality of Life Research.

[27]  Christina Holcroft,et al.  Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial , 2014, The Lancet.

[28]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[29]  S. Kahn,et al.  Risk of post‐thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study , 2012, Journal of thrombosis and haemostasis : JTH.

[30]  R. Hull,et al.  Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. , 2011, The American journal of medicine.

[31]  P. Prandoni,et al.  The postthrombotic syndrome , 2010, Internal and emergency medicine.

[32]  S. Kahn.  How I treat postthrombotic syndrome. , 2009, Blood.

[33]  S. Kahn.  Measurement properties of the Villalta scale to define and classify the severity of the post‐thrombotic syndrome , 2009, Journal of thrombosis and haemostasis : JTH.

[34]  P. Prandoni,et al.  Definition of post‐thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization , 2009, Journal of thrombosis and haemostasis : JTH.

[35]  D. Lamping,et al.  Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. , 2008, Annals of internal medicine.

[36]  D. Lamping,et al.  VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis. , 2006, Journal of clinical epidemiology.

[37]  M. Prins,et al.  Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome , 2005, Journal of thrombosis and haemostasis : JTH.

[38]  M. Prins,et al.  Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: A randomized, controlled trial , 2005 .

[39]  John E. Brazier,et al.  Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D , 2005, Quality of Life Research.

[40]  G. Norman,et al.  The truly remarkable universality of half a standard deviation: confirmation through another look , 2004, Expert review of pharmacoeconomics & outcomes research.

[41]  M. Prins,et al.  Below-Knee Elastic Compression Stockings To Prevent the Post-Thrombotic Syndrome , 2004, Annals of Internal Medicine.

[42]  S. Schroter,et al.  Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. , 2003, Journal of vascular surgery.

[43]  S. Kahn,et al.  Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. , 2002, Archives of internal medicine.

[44]  D. Bergqvist,et al.  Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden , 1997, Annals of Internal Medicine.

[45]  H. Büller,et al.  Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis , 1997, The Lancet.

[46]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[47]  J. E. Brazier,et al.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care. , 1992, BMJ.

[48]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[49]  D. Strandness,et al.  Long-term sequelae of acute venous thrombosis. , 1983, JAMA.